Clinical Trial Update: A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse [Phase 3]

View source ↗

Summary

A Phase 3 study of tanespimycin (KOS-953) in patients with multiple myeloma at first relapse has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tanespimycin (KOS-953) (tanespimycin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED